Valiant Organics Ltd

The transcript does not provide specific details about the current or expected order book or pending orders for Valiant Organics Ltd. However, some relevant points can be inferred: - Demand is currently significantly impacted with volume drops of around 14-15% and price reduction around 10% at the company level. - Capacity utilization is running at about 50%, with some products (e.g., PAP) affected by shutdowns. - Outlook for Pharma intermediates and OAP is cautious; OAP commercialization is delayed due to quality issues. - The company expects some turnaround in the market in Q3 and Q4, but overall demand remains weak in Q1 and Q2. - No explicit quantitative guidance on order book or pending orders was mentioned during the call. If you need detailed order book data, it may be best to refer to official company filings or directly contact the company.

- As of the Q1 FY24 call, Valiant Organics reported total debt of around INR 190-195 crores (term loan ~INR 90 crores and short-term ~INR 91-92 crores). - The company is not considering taking any significant new debt currently but plans to revisit the need depending on market conditions in a couple of months. - Term loans are being repaid as scheduled, with INR 40-45 crores expected to be repaid in FY24 and loans targeted to be fully repaid by FY26. - Regarding equity/fundraising from promoters, the management did not comment on any further promoter dilution or stake sale plans due to multiple promoters involved; no specific future equity fundraising was announced. - The company is focusing on planned CapEx with possible slight postponement but no major changes to expansion plans.

- The company is revisiting its CapEx plans due to the current demand slowdown but intends to continue with the projects, possibly delaying some by a quarter or so. - CapEx has been substantial over the past four to five years, spread across phases including chlorination, hydrogenation, ammonolysis expansions, PAP (a new Greenfield project), backward integration of OA and PA, OAP ongoing, and Pharma Intermediate project commercialization. - No significant new debt is planned currently; peak debt is estimated around INR 190-195 crores, with ongoing repayments targeted to clear term loans by FY26. - Investments include introduction of renewable captive energy plant (2.2 MW wind power) expected to yield INR 2.5-3 crores annual savings. - Process automation through DCS systems is being implemented to improve efficiency. - No major new strategic investments or expansions have been announced; focus is on ramping up and stabilizing current projects.

- Revenue guidance for FY24 has been revised down from INR 1,200 crore to INR 800-850 crore due to weak demand and price corrections. (Page 7, 14) - Expected degrowth in revenue is around 5-10% for the year, driven by overall demand slowdown. (Page 6) - Volume degrowth company-wide is approximately 14-15%, while price decline contributes about 10%. (Page 16) - Pharma segment seen as a growth driver; PAP projected at INR 170-180 crore, possibly up to INR 200 crore, lower than earlier estimates. (Page 15) - Pharma Intermediate Project recently commercialized and expected to contribute around INR 60-65 crore yearly, but negligible contribution in current quarter. (Page 15) - Ramp-up of PAP capacity is targeted to reach around 900 MT/month by year-end, conditional on market demand. (Page 12) - Anticipated demand improvement expected in Q3 and Q4, particularly in textile segment; however, near-term demand remains weak. (Pages 6, 10) - Demand for dyes, pigments, and agrochemical segments are subdued. (Page 14)

- The company anticipates a difficult year for FY24 with expected revenue degrowth of around 5-10% due to weak demand and pricing pressures. - EBITDA margins are projected to be between 12-15%, revised down from earlier guidance of 20% because of demand slowdowns in textiles, agrochemicals, and pricing corrections. - Pharma segment expected to grow, but price corrections in PAP products will impact margins; PAP revenue guidance revised down to INR 170-180 crores from INR 300 crores. - Pharma Intermediates segment is in early stages; expected full-year contribution is INR 60-65 crores. - The company expects some demand improvement in Q3 and Q4, but overall scenario remains uncertain. - CapEx plans continue but may see slight delays; peak debt expected around INR 190-195 crores. - Operational efficiencies are being enhanced through renewable energy and automation but employee costs are not expected to decline. Overall, cautious outlook with subdued earnings growth in near term.